Salute e Benessere
Kexing Biopharm's Albumin-bound Paclitaxel Granted EU Market Approval
In recent years, the Chinese pharmaceutical industry has embarked on a significant expansion into international markets. But actually, Kexing Biopharm began its international ventures 20 years ago with its core products. In recent years, the company has introduced more than a dozen high-quality Chinese medications to emerging markets, improving accessibility to medicines for local patients.
The approval of albumin-bound paclitaxel by the EU will enhance the company's competitiveness in the international pharmaceutical market. It also signifies that Kexing Biopharm, in addition to its long-established presence in emerging markets, is expanding its commercialization efforts into the European market. The EU market represents an important milestone in the company's overseas commercialization strategy. To date, Kexing Biopharm is proceeding with the registration of Apexelsin in dozens of emerging market out of Europe . With the successful launch of this product in the EU, Kexing Biopharm will further expand its global sales reach, serving more patients and healthcare providers.
View original content:https://www.prnewswire.co.uk/news-releases/kexing-biopharms-albumin-bound-paclitaxel-granted-eu-market-approval-302210954.html